Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Layton

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Drug Safety|January 29, 2016
Vulnerable Patients and Potential Harms: The Contribution of Observational ResearchDeborah Layton
Drug Safety|December 15, 2010
New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UKElizabeth Lynn, Deborah Layton, Saad Shakir
Drug Safety|June 20, 2002
Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteriaSaad A W Shakir, Deborah Layton
Frontiers in Drug Safety and Regulation|September 22, 2025
Editorial: External control arms for single-arm studies: methodological considerations and applicationsDeborah Layton, Laura Hester, Asieh Golozar
Drug Safety|January 8, 2015
Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilanceDeborah Layton, Saad A W Shakir
Post Reproductive Health|June 1, 2014
Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch)Vicki Osborne, Deborah Layton, Saad Aw Shakir
Pharmacoepidemiology and Drug Safety|May 10, 2002
Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safetyCheryl Key, Deborah Layton, Saad A W Shakir
Pharmacoepidemiology and Drug Safety|March 6, 2003
Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the futureDeborah Layton, Cheryl Key, Saad A W Shakir
Drug Safety|February 25, 2009
Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in EnglandDeborah Layton, Lynda Wilton, Saad A W Shakir
Drug Safety|November 15, 2011
Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk managementDeborah Layton, Lorna Hazell, Saad A W Shakir
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Drug Safety|January 29, 2016
Vulnerable Patients and Potential Harms: The Contribution of Observational ResearchDeborah Layton
Drug Safety|December 15, 2010
New postgraduate qualifications in pharmacovigilance from the Drug Safety Research Unit in the UKElizabeth Lynn, Deborah Layton, Saad Shakir
Drug Safety|June 20, 2002
Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteriaSaad A W Shakir, Deborah Layton
Frontiers in Drug Safety and Regulation|September 22, 2025
Editorial: External control arms for single-arm studies: methodological considerations and applicationsDeborah Layton, Laura Hester, Asieh Golozar
Drug Safety|January 8, 2015
Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilanceDeborah Layton, Saad A W Shakir
Post Reproductive Health|June 1, 2014
Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch)Vicki Osborne, Deborah Layton, Saad Aw Shakir
Pharmacoepidemiology and Drug Safety|May 10, 2002
Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safetyCheryl Key, Deborah Layton, Saad A W Shakir
Pharmacoepidemiology and Drug Safety|March 6, 2003
Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the futureDeborah Layton, Cheryl Key, Saad A W Shakir
Drug Safety|February 25, 2009
Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in EnglandDeborah Layton, Lynda Wilton, Saad A W Shakir
Drug Safety|November 15, 2011
Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk managementDeborah Layton, Lorna Hazell, Saad A W Shakir
Pageof 6